A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso

A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso

Objectives

To study of the safety of MSP 3 LSP candidate malaria vaccine in children aged 1-2 years in Burkina Faso. Three imminizations at 28 day intervals will be administratered subcuteneously on the shoulder region. The study will compare MSP3 with Engerix B vaccine to evaluate whether it is just as safe to give to children in malaria endemic country. The study will also evaluate whether the vaccine induces the expected immune responses. Two dose levels of MSP 3 will be evaluated; 15µg and 30µg to determine the one with the best safety and immune response profile.

PI Institution(s)

Principal Investigator (PI)

Funding source(s)

Partner(s)

https://clinicaltrials.gov/ct2/show/NCT00452088

Key facts

  • Dates
    Apr 2007 to May 2008
    Country
    • Burkina Faso

MESA tags

  • Methodology
    Product development & clinical research
    Theme(s)
    Immune correlates of protection